Bespak – the specialist CDMO for inhaled and nasal drug delivery
Bespak® is a global Contract Development and Manufacturing Organisation (CDMO) specialising in inhaled and nasal drug delivery. Headquartered in Holmes Chapel, UK, the company develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical industry. Bespak provides a fully integrated service to support customers from early-stage feasibility, analytical and formulation development, product development and clinical supply, through to full-scale cGMP batch production.
Leveraging established capabilities, ongoing manufacturing expansions, and collaborations across the supply chain, Bespak is leading the transition to low carbon pMDIs and is the first CDMO with commercial manufacturing capacity for low Global Warming Potential (GWP) propellants.
To accelerate the path from early pMDI development to commercial supply, the CDMO applies a digital-first approach. Digital modelling and simulation tools help developers understand the distinct physical and chemical properties of both HFA-152a and HFO-1234ze(E), from formulation behaviour and valve refill dynamics to hardware optimisation and manufacturing readiness.
Bespak combines these manufacturing capabilities with next-generation pMDI components. The CDMO already supplies a major proportion of the world’s pMDI metering valves and actuators, including the trusted, market approved BK357 valve — the first pMDI valve approved for use with a low GWP propellants. Customers can further future-proof their pMDIs through Bespak’s next-generation integrated dose-by-dose counter.
Bespak specialises in the industrialisation and high-volume manufacture of complex Dry Powder Inhaler (DPI) devices, as well as unit dose and multi dose nasal sprays, offering industry-leading contract manufacturing services at all scales.
Across drug-device combination product development and manufacturing, Bespak delivers industry-leading quality supported by continuous improvement. Investing in the long-term capabilities of its workforce, the company’s unique Injection Moulding Academy enables technological innovation through expert-led training in inhalation device manufacture. Bespak also recognises the complexity of regulatory pathways for drug-device combination products and provides specialist support to help de-risk and streamline development.
Through a joint venture with Medspray, Bespak offers Resyca® Soft Mist Inhalers (SMIs) and ultrasoft nasal sprays. These harness proprietary spray nozzle technology to efficiently deliver sensitive formulations, including biologics, to the lungs or nasal cavity.
Bespak’s expanding capabilities are strengthened by significant investment and strategic collaborations. Working alongside its partners, Bespak is helping to lead the inhalation industry to a more sustainable future and supporting continued patient access to life-saving treatments.
Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. This commitment extends across its operations, as Bespak prioritises strong environmental, social and governance (ESG) strategies to build responsible business practices and establish itself as a trusted partner for its customers.
Bespak
London Rd, Holmes Chapel, Crewe, United Kingdom, CW4 8BE
More information: www.bespak.com
